Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging

Alzheimer's and Dementia

Volumn 10, Issue 1 SUPPL., 2014, Pages

  Femminella, Grazia D ^a   Edison, Paul ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid imaging; FDG PET; Glucagon like peptide 1; Liraglutide; MRI; Neuroimaging; Neuroinflammation; Parkinson's disease

Indexed keywords

AMYLOID; FLUORODEOXYGLUCOSE F 18; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG MECHANISM; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; MICROGLIA; MULTICENTER STUDY (TOPIC); NERVE FIBER GROWTH; NEURAL STEM CELL; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ALZHEIMER'S DISEASE; AMYLOID IMAGING; FDG-PET; GLUCAGON-LIKE PEPTIDE 1; LIRAGLUTIDE; MRI; NEUROIMAGING; NEUROINFLAMMATION; PARKINSON'S DISEASE;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MICE; MICE, TRANSGENIC; NEURODEGENERATIVE DISEASES; NEUROIMAGING; NEUROPROTECTIVE AGENTS;

EID: 84897834287     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.12.012     Document Type: Review

References (60)

1. K. Akter, E.A. Lanza, S.A. Martin, N. Myronyuk, M. Rua, and R.B. Raffa Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 71 2011 365 376
2. J.A. Lovshin, and D.J. Drucker Incretin-based therapies for type 2 diabetes mellitus Nat Rev Endocrinol 5 2009 262 269
3. P.L. McClean, and C. Hölscher Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease Neuropharmacology 76 2014 57 67
4. I. Aviles-Olmos, J. Dickson, Z. Kefalopoulou, A. Djamshidian, P. Ell, and T. Soderlund et al. Exenatide and the treatment of patients with Parkinson's disease J Clin Invest 123 2013 2730 2736
5. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, and P. Barberger-Gateau et al. Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
6. K. Herholz Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease Biomark Med 6 2012 431 439
7. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, and P.S. Aisen et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216
8. K. Herholz, E. Salmon, D. Perani, J.C. Baron, V. Holthoff, and L. Frolich et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET Neuroimage 17 2002 302 316
9. A. Drzezga, N. Lautenschlager, H. Siebner, M. Riemenschneider, F. Willoch, and S. Minoshima et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study Eur J Nucl Med Mol Imaging 30 2003 1104 1113
10. D. Anchisi, B. Borroni, M. Franceschi, N. Kerrouche, E. Kalbe, and B. Beuthien-Beumann et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease Arch Neurol 62 2005 1728 1733
11. G. Chetelat, F. Eustache, F. Viader, V. De La Sayette, A. Pelerin, and F. Mezenge et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment Neurocase 11 2005 14 25
12. S.M. Landau, D. Harvey, C.M. Madison, R.A. Koeppe, E.M. Reiman, and N.L. Foster et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI Neurobiol Aging 32 2011 1207 1218
13. K. Herholz, S. Westwood, C. Haense, and G. Dunn Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment J Nucl Med 52 2011 1218 1226
14. K.A. Johnson, N.C. Fox, R.A. Sperling, and W.E. Klunk Brain imaging in Alzheimer disease Cold Spring Harbor Perspect Med 2 2012 a006213
15. G.B. Frisoni, N.C. Fox, C.R. Jack Jr., P. Scheltens, and P.M. Thompson The clinical use of structural MRI in Alzheimer disease Nat Rev Neurol 6 2010 67 77
16. J. Barnes, S. Ourselin, and N.C. Fox Clinical application of measurement of hippocampal atrophy in degenerative dementias Hippocampus 19 2009 510 516
17. S.J. Teipel, M. Grothe, S. Lista, N. Toschi, F.G. Garaci, and H. Hampel Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease Med Clin N Am 97 2013 399 424
18. I. Salcedo, D. Tweedie, Y. Li, and N.H. Greig Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders Br J Pharmacol 166 2012 1586 1599
19. P. Edison, R. Hinz, and D.J. Brooks Technical aspects of amyloid imaging for Alzheimer's disease Alzheimers Res Ther 3 2011 25
20. V.L. Villemagne, W.E. Klunk, C.A. Mathis, C.C. Rowe, D.J. Brooks, and B.T. Hyman et al. Abeta imaging: feasible, pertinent, and vital to progress in Alzheimer's disease Eur J Nucl Med Mol Imaging 39 2012 209 219
21. H. Engler, A. Forsberg, O. Almkvist, G. Blomquist, E. Larsson, and I. Savitcheva et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease Brain 129 2006 2856 2866
22. C.R. Jack Jr., V.J. Lowe, S.D. Weigand, H.J. Wiste, M.L. Senjem, and D.S. Knopman et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain 132 2009 1355 1365
23. C.R. Jack Jr., V.J. Lowe, M.L. Senjem, S.D. Weigand, B.J. Kemp, and M.M. Shiung et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain 131 2008 665 680
24. C.C. Rowe, S. Ng, U. Ackermann, S.J. Gong, K. Pike, and G. Savage et al. Imaging beta-amyloid burden in aging and dementia Neurology 68 2007 1718 1725
25. B.J. Lopresti, W.E. Klunk, C.A. Mathis, J.A. Hoge, S.K. Ziolko, and X. Lu et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis J Nucl Med 46 2005 1959 1972
26. J. Koivunen, N. Scheinin, J.R. Virta, S. Aalto, T. Vahlberg, and K. Nagren et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study Neurology 76 2011 1085 1090
27. W.J. Jagust, D. Bandy, K. Chen, N.L. Foster, S.M. Landau, and C.A. Mathis et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core Alzheimers Dement 6 2010 221 229
28. V.L. Villemagne, K.E. Pike, G. Chetelat, K.A. Ellis, R.S. Mulligan, and P. Bourgeat et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease Ann Neurol 69 2011 181 192
29. R. Ossenkoppele, B.N. van Berckel, and N.D. Prins Amyloid imaging in prodromal Alzheimer's disease Alzheimers Res Ther 3 2011 26
30. A. Forsberg, H. Engler, O. Almkvist, G. Blomquist, G. Hagman, and A. Wall et al. PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol Aging 29 2008 1456 1465
31. A. Okello, J. Koivunen, P. Edison, H.A. Archer, F.E. Turkheimer, and K. Nagren et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study Neurology 73 2009 754 760
32. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, and R.C. Green et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 9 2013 e111 e194
33. T. Perry, D.K. Lahiri, K. Sambamurti, D. Chen, M.P. Mattson, and J.M. Egan et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron J Neurosci Res 72 2003 603 612
34. W.N. Han, C. Holscher, L. Yuan, W. Yang, X.H. Wang, and M.N. Wu et al. Liraglutide protects against amyloid-beta protein-induced impairment of spatial learning and memory in rats Neurobiol Aging 34 2013 576 588
35. P.L. McClean, V. Parthsarathy, E. Faivre, and C. Holscher The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease J Neurosci 31 2011 6587 6594
36. L. Egefjord, M. Gejl, A. Moller, H. Braendgaard, H. Gottrup, and O. Antropova et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease - protocol for a controlled, randomized double-blinded trial Dan Med J 59 2012 A4519
37. R.B. Banati Visualising microglial activation in vivo Glia 40 2002 206 217
38. R.B. Banati, J. Newcombe, R.N. Gunn, A. Cagnin, F. Turkheimer, and F. Heppner et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity Brain 123 2000 2321 2337
39. M.K. Chen, K. Baidoo, T. Verina, and T.R. Guilarte Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization Brain 127 2004 1379 1392
40. A. Martin, R. Boisgard, B. Theze, N. van Camp, B. Kuhnast, and A. Damont et al. Evaluation of the PBR/TSPO radioligand [(18)F]DPA-714 in a rat model of focal cerebral ischemia J Cereb Blood Flow Metab 30 2010 230 241
41. S. Venneti, G. Wang, J. Nguyen, and C.A. Wiley The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders J Neuropathol Exp Neurol 67 2008 1001 1010
42. P. Charbonneau, A. Syrota, C. Crouzel, J.M. Valois, C. Prenant, and M. Crouzel Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography Circulation 73 1986 476 483
43. P.L. McGeer, S. Itagaki, B.E. Boyes, and E.G. McGeer Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 38 1988 1285 1291
44. S. Venneti, B.J. Lopresti, G. Wang, R.L. Hamilton, C.A. Mathis, and W.E. Klunk et al. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET Neurobiol Aging 30 2009 1217 1226
45. S.A. Frautschy, F. Yang, M. Irrizarry, B. Hyman, T.C. Saido, and K. Hsiao et al. Microglial response to amyloid plaques in APPsw transgenic mice Am J Pathol 152 1998 307 317
46. A. Cagnin, D.J. Brooks, A.M. Kennedy, R.N. Gunn, R. Myers, and F.E. Turkheimer et al. In-vivo measurement of activated microglia in dementia Lancet 358 2001 461 467
47. P. Edison, H.A. Archer, A. Gerhard, R. Hinz, N. Pavese, and F.E. Turkheimer et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study Neurobiol Dis 32 2008 412 419
48. A. Okello, P. Edison, H.A. Archer, F.E. Turkheimer, J. Kennedy, and R. Bullock et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study Neurology 72 2009 56 62
49. C.A. Wiley, B.J. Lopresti, S. Venneti, J. Price, W.E. Klunk, and S.T. DeKosky et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease Arch Neurol 66 2009 60 67
50. W.C. Kreisl, M. Fujita, Y. Fujimura, N. Kimura, K.J. Jenko, and P. Kannan et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker Neuroimage 49 2010 2924 2932
51. D.R. Owen, R.N. Gunn, E.A. Rabiner, I. Bennacef, M. Fujita, and W.C. Kreisl et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands J Nucl Med 52 2011 24 32
52. D.R. Owen, A.J. Yeo, R.N. Gunn, K. Song, G. Wadsworth, and A. Lewis et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 J Cereb Blood Flow Metab 32 2012 1 5
53. T. Iwai, S. Ito, K. Tanimitsu, S. Udagawa, and J. Oka Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes Neurosci Res 55 2006 352 360
54. D.J. Brooks, and N. Pavese Imaging biomarkers in Parkinson's disease Prog Neurobiol 95 2011 614 628
55. B.J. Snow, I. Tooyama, E.G. McGeer, T. Yamada, D.B. Calne, and H. Takahashi et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels Ann Neurol 34 1993 324 330
56. B.D. Pate, T. Kawamata, T. Yamada, E.G. McGeer, K.A. Hewitt, and B.J. Snow et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices Ann Neurol 34 1993 331 338
57. M. Otsuka, Y. Ichiya, Y. Kuwabara, S. Hosokawa, M. Sasaki, and T. Yoshida et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms J Neurol Sci 136 1996 169 173
58. E. Nurmi, H.M. Ruottinen, V. Kaasinen, J. Bergman, M. Haaparanta, and O. Solin et al. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT Ann Neurol 47 2000 804 808
59. G. Bertilsson, C. Patrone, O. Zachrisson, A. Andersson, K. Dannaeus, and J. Heidrich et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease J Neurosci Res 86 2008 326 338
60. A. Harkavyi, A. Abuirmeileh, R. Lever, A.E. Kingsbury, C.S. Biggs, and P.S. Whitton Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease J Neuroinflammation 5 2008 19